• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.

作者信息

Boccon-Gibod Clémentine, Talbot Alexis, Le Bras Fabien, Frenzel Laurent, Royer Bruno, Harel Stephanie, Lombion Naelle, Belhadj Karim, Cuccuini Wendy, Arnulf Bertrand

机构信息

Immuno-hematology Department, Hôpital Saint-Louis, APHP, Paris, France.

Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.

出版信息

Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3.

DOI:10.1111/bjh.16483
PMID:32012229
Abstract
摘要

相似文献

1
Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.卡非佐米、维奈克拉和地塞米松用于复发/难治性多发性骨髓瘤
Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3.
2
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.来那度胺联合卡非佐米和地塞米松治疗伴有 t(11,14)(q13;q32)的复发/难治性多发性骨髓瘤：两例病例报告及文献复习。
J Med Case Rep. 2020 Apr 23;14(1):54. doi: 10.1186/s13256-020-02376-y.
3
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.地塞米松治疗可促进多发性骨髓瘤对Bcl-2的依赖性，从而导致对维奈托克敏感。
Leukemia. 2016 May;30(5):1086-93. doi: 10.1038/leu.2015.350. Epub 2015 Dec 28.
4
Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.维奈托克联合卡非佐米、阿霉素和地塞米松可恢复一名原本治疗难治性多发性骨髓瘤患者的反应性。
Haematologica. 2020 Mar;105(3):e138-e140. doi: 10.3324/haematol.2019.232330. Epub 2019 Aug 29.
5
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Venetoclax 联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤的 II 期研究。
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):775-784. doi: 10.1016/j.clml.2021.07.029. Epub 2021 Aug 1.
6
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.低剂量维奈托克联合硼替佐米、达雷妥尤单抗和地塞米松治疗复发/难治性多发性骨髓瘤患者的单中心回顾性研究。
Ann Hematol. 2021 Aug;100(8):2061-2070. doi: 10.1007/s00277-021-04555-3. Epub 2021 May 14.
7
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.硼替佐米和地塞米松联合维奈托克治疗复发/难治性多发性骨髓瘤显示出良好的疗效和可接受的安全性。
Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.
8
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Venetoclax 联合达雷妥尤单抗和地塞米松，加或不加硼替佐米，治疗伴有和不伴有 t(11;14)的复发/难治性多发性骨髓瘤的 I 期研究。
J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13.
9
Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.用一例对维奈托克敏感的难治性疾病解释多发性骨髓瘤中t(11;14)的生物学意义
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e556-e559. doi: 10.1016/j.clml.2020.05.028. Epub 2020 Jun 14.
10
Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.每周卡非佐米联合地塞米松治疗复发或难治性多发性骨髓瘤的日本患者：一项 I 期和药代动力学/药效学研究。
Cancer Sci. 2018 Oct;109(10):3245-3252. doi: 10.1111/cas.13753. Epub 2018 Sep 5.

引用本文的文献

1
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.靶向MARCH5-MFN2轴以增强线粒体融合并使多发性骨髓瘤细胞对维奈托克敏感。
J Transl Med. 2025 Aug 14;23(1):917. doi: 10.1186/s12967-025-06942-0.
2
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.BCL-2抑制剂与免疫疗法联合应用：血液系统恶性肿瘤的一种有前景的治疗策略。
Discov Oncol. 2024 Jul 26;15(1):311. doi: 10.1007/s12672-024-01161-3.
3
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
维奈托克耐药导致对标准治疗抗多发性骨髓瘤药物的广泛耐药，但对免疫疗法无耐药性。
Blood Adv. 2024 Aug 13;8(15):4025-4034. doi: 10.1182/bloodadvances.2023012298.
4
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).伴有 t(6;14)易位的复发/难治性多发性骨髓瘤患者中有效的维奈托克治疗。
Pathol Oncol Res. 2023 Nov 10;29:1611375. doi: 10.3389/pore.2023.1611375. eCollection 2023.
5
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency.t(11;14)多发性骨髓瘤的整合表观遗传和转录单细胞分析及其 BCL2 依赖性。
Blood. 2024 Jan 4;143(1):42-56. doi: 10.1182/blood.2023020276.
6
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study.维奈克拉治疗复发/难治性轻链型淀粉样变性——一项多中心国际回顾性真实世界研究
Cancers (Basel). 2023 Mar 10;15(6):1710. doi: 10.3390/cancers15061710.
7
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis.基于维奈托克的方案治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项系统评价和荟萃分析。
Ther Adv Hematol. 2023 Mar 6;14:20406207231155028. doi: 10.1177/20406207231155028. eCollection 2023.
8
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.多发性骨髓瘤下一代新型疗法的毒性管理策略
Ther Adv Hematol. 2022 Jul 15;13:20406207221100659. doi: 10.1177/20406207221100659. eCollection 2022.
9
Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.胰岛素降解酶是卡非佐米的非蛋白酶体靶标，并影响该药物对 20S 蛋白酶体的抑制作用。
Biomolecules. 2022 Feb 16;12(2):315. doi: 10.3390/biom12020315.
10
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.多发性骨髓瘤治疗中免疫治疗之外的新型方法：美法仑氟芬、维奈克拉和塞利尼索的案例
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.